Oncogenic osteomalacia: loss of hypophosphatemia might be the key to avoid misdiagnosis

• Autor(a) principal: Chang,Claudia V.
• Data de Publicação: 2012
• Outros Autores: Conde,Sandro J., Luvizotto,Renata A. M., Nunes,Vânia S., Bonates,Milla C., Felicio,Andre C., Lindsey,Susan C., Moraes,Flávia H., Tagliarini,José V., Mazeto,Glaucia M. F. S., Kopp,Peter, Nogueira,Célia R.
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Arquivos Brasileiros de Endocrinologia & Metabologia (Online)
• Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27302012000800018

Diagnosing oncogenic osteomalacia is still a challenge. The disorder is characterized by osteomalacia caused by renal phosphate wasting and low serum concentration of 1,25-dihydroxyvitamin D3 occurring in the presence of a tumor that produces high levels of fibroblast growth factor 23. However, it is possible that the disease is much more misdiagnosed than rare. We present the case of a 42-year-old man with a long-term history of undiagnosed progressive muscle weakness. His laboratory results mainly showed low serum phosphate. Surgical removal of a nasal hemangiopericytoma that had been diagnosed five years earlier, brought him to a symptom-free condition. Even though knowing the underlying etiology would explain his osteomalacia, the patient sought medical help from countless physicians for five consecutive years, and only after adequate treatment a rewarding outcome was achieved. Arq Bras Endocrinol Metab. 2012;56(8):570-3